Effects of perindopril and valsartan on expression of transforming growth factor-β-Smads in experimental hepatic fibrosis in rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 8, 2006, Pages 1250-1256

  Xu, Wei ^a   Song, Shiling ^a   Huang, Yanqing ^a   Gong, Zuojiong ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Angiotensin II inhibitor; Angiotensin II receptor antagonist; Hepatic fibrosis; Smad; Transforming growth factor type II receptor; Transforming growth factor 1

Indexed keywords

MESSENGER RNA; PERINDOPRIL; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VALSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTRON MICROSCOPY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER; LIVER FIBROSIS; LIVER FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

EID: 33745843718     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04331.x     Document Type: Article

References (32)

1. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002; 123: 1667-76.
2. Border WA, Noble N. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin. Nephrol. 2001; 21: 563-72.
3. Yoshiji H, Yoshii J, Ikenaka Y et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J. Hepatol. 2002; 37: 22-30.
4. Isono M, Soda M, Inoue A, Akiyoshi H, Sato K. Reverse transformation of hepatic myofibroblast-like cells by TGFbeta1/LAP. Biochem. Biophys. Res. Commun. 2003; 311: 959-65.
5. Dooley S, Delvoux B, Streckert M et al. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett. 2001; 502: 4-10.
6. Chevallier M, Gueerret S, Chossegros P, Gerard F, Grimaud JA. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studyies. Hepatology 1994; 20: 349-55.
7. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of hepatic fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002; 23: 348-56.
8. Yoshiji H, Kuriyama S, Yoshii J et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-50.
9. 4. Chin. Med. J. 2001; 114: 583-7.
10. Tahashi Y, Matsuzaki K, Date M et al. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002; 35: 49-61.
11. Napoli J, Prentice D, Niinami C, Bishop GA, Desmond P, McCaughan GW. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated rat model of cirrhosis. Hepatology 1997; 26: 624-33.
12. Le Pabic H, Bonnier D, Wewer UM et al. ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003; 37: 1056-66.
13. Okuno M, Akita K, Moriwaki H et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001; 120: 1784-800.
14. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature 1988; 334: 260-2.
15. Balza E, Borsi L, Allemanni G, Zardi L. Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett. 1988; 228: 42-4.
16. Roulot D, Sevcsik AM, Coste T, Strosberg AD, Marullo S. Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology 1999; 29: 1730-8.
17. George J, Roulot D, Victor E, Koteliansky D, Bissell M. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl Acad. Sci. USA 1999; 96: 12719-24.
18. Inagaki M, Moutakas A, Lin HY, Lodish HF, Carr BI. Growth inhibition by transforming growth factor β (TGF-β) type I is restored in TGF-β-resistant hepatoma cells after expression of TGF-β receptor type II cDNA. Proc. Natl Acad. Sci. USA 1993; 90: 5359-63.
19. Bassing CH, Yingling JM, Howe DJ et al. A transforming growth factor beta type I receptor that signals to activate gene expression. Science 1994; 263: 87-9.
20. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr. Opin. Cell Biol. 2000; 12: 235-43.
21. Dong C, Zhu S, Wang T et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc. Natl Acad. Sci. USA 2002; 99: 3908-13.
22. Imamura TM, Takase M, Nishihara A et al. Smad6 inhibits signaling by the TGF-beta superfamily. Nature 1997; 389: 622-6.
23. Carcamo J, Weis FM, Ventura F et al. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol. Cell Biol. 1994; 14: 3810-21.
24. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998; 95: 737-40.
25. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano Y, Yamagata H, Matsushita M, Seki T, Inagaki Y, Nishizawa M, Fujisawa J, Inoue K. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003; 38: 879-89.
26. Stopa M, Benes V, Ansorge W, Gressner AM, Dooley S. Genomic locus and promoter region of rat Smad7, an important antagonist of TGF-beta signaling. Mamm. Genome 2000; 11: 169-76.
27. Li X, Ionescu AM, Schwarz EM et al. Smad6 is induced by BMP-2 and modulates chondrocyte differentiation. J. Orthop. Res. 2003; 21: 908-13.
28. Ishisaki A, Yamato S, Hashimoto A et al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J. Biol. Chem. 1999; 274: 13637-42.
29. Hayashi H, Abdollah S, Qiu Y et al. The MAD-related protein Smad7 associates with the TGF-beta receptor and functions as an antagonist of TGF-beta signaling. Cell 1997; 89: 1165-73.
30. Souchelnytskyi ST, Nakayama A, Nakao A et al. Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-receptors. J. Biol. Chem. 1998; 273: 25364-70.
31. Nakao A, Afrakhte M, Moren A et al. Identification of Smad7, a TGF-beta-inducible antagonist of TGF-beta signaling. Nature 1997; 389: 631-5.
32. Datta PK, Moses HL. STRAP and Smad7 synergize in the inhibition of transforming growth factor beta signaling. Mol. Cell Biol. 2000; 20: 3157-67.